MG
MDGL icon

Marex Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Marex Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$653K Sell
1,216
-513
-30% -$263K ﹤0.01% 617
2026
Q1 		$905K Buy
+1,729
New +$826K 0.01% 462
2025
Q3 		– Sell
-1,811
Closed -$548K – 951
2025
Q2 		$548K Buy
1,811
+1,087
+150% +$324K ﹤0.01% 365
2025
Q1 		$240K Buy
+724
New +$238K ﹤0.01% 530

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marex Group's MDGL Position: Q2 2026 in Review

Marex Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 30% in Q2 2026, selling an estimated $263K and leaving 1,216 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #617.

Marex Group first reported a position in MDGL in Q1 2025 and has held it in 4 quarters since. The position peaked at $905K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Marex Group held 1,216 shares of Madrigal Pharmaceuticals worth $653K as of Q2 2026.
  • Marex Group sold 513 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $263K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #617 holding.
  • Marex Group first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Marex Group's Madrigal Pharmaceuticals position peaked at $905K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.